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Prions causetransmissibleneurodegenerative diseases andreplicate byconformational conversionof
normal benignforms ofprionprotein(PrP
C) todisease-causing PrP
Scisoforms. A systems approach to
disease postulates that disease arises from perturbation of biological networks in the relevant organ.
We tracked global gene expression in the brains of eight distinct mouse strain–prion strain
combinations throughout the progression of the disease to capture the effects of prion strain, host
genetics, and PrP concentration on disease incubation time. Subtractive analyses exploiting various
aspects of prion biology and infection identiﬁed a core of 333 differentially expressed genes (DEGs)
that appeared central to prion disease. DEGs were mapped into functional pathways and networks
reﬂecting deﬁned neuropathological events and PrP
Sc replication and accumulation, enabling the
identiﬁcationofnovelmodulesandmodulesthatmaybeinvolvedingeneticeffectsonincubationtime
and in prion strain speciﬁcity. Our systems analysis provides a comprehensive basis for developing
models for prion replication and disease, and suggests some possible therapeutic approaches.
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Introduction
Systems approaches to disease arise from a simple hypoth-
esis—disease emerges from the functioning of one or more
disease-perturbed networks (genetic and/or environmental
perturbations) that alter the levels of proteins and other
informational molecules controlled by these networks. The
dynamically changing levels of disease-perturbed proteins
(networks) across disease progression presumably explain
the mechanisms of the disease. Systems approaches to biology
or medicine have two cardinal features: (1) global analyses to
generate comprehensive data sets in thedisease-relevantorgan
or cells across the dynamically changing disease process (e.g.
all mRNA, miRNA, or protein levels) and (2) the integration of
different levels of biological information (DNA, mRNA,
miRNA, protein, interactions, metabolites, networks, tissues,
organs, and phenotypes) to generate hypotheses about the
fundamentalprinciplesofthedisease(Hoodetal,2004).Inthis
study, we present a systems biology approach that effectively
uses these two features, uses multiple inbred mouse strains,
uses a deep understanding of prion biology and applies
statistical data integration methods to deal with two striking
challenges: (1) sorting out the signal-to-noise issues arising
from the global disease-associated changes as both measure-
ment noise and biological noise and (2) reducing enormous
data dimensionality so that the processes can be identiﬁed and
visualized for study. The keys to reducing this noise are to
apply a deep understanding of biology to carry out subtractive
dataanalysesthatfocusonparticularbiologicalissues—aswell
as to use integrative statistical methods. We applied the
systems approach to experimentally tractable neurodegenera-
tive diseases caused by prion infection of mice. Analysis of a
large data set (B20 million data points) revealed slightly more
than 300 differentially expressed genes (DEGs) that may
encode fundamental processes in prion disease.
Prions are unique among transmissible, disease-causing
agents in that they replicate by conformational conversion of
normalbenignformsofprionprotein(PrP
C)todisease-speciﬁc
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Sc isoforms. Neuropathological features common to all
prion diseases in mammals, which include bovine spongiform
encephalopathy (BSE) in cows, Creutzfeldt–Jakob disease
(CJD) in humans, and scrapie in sheep, can be conveniently
subdivided into four processes: prion (PrP
Sc) replication
and accumulation (Prusiner, 2003), synaptic degeneration
(Ishikura et al, 2005), microglia and astrocyte activation
(Rezaie and Lantos, 2001; Perry et al, 2002), and neuronal cell
death (Liberski et al, 2004). There exist distinct strains of
infectious prions that have different properties (e.g. duration
of incubation time, sites of infection in the brain, and so on)
that presumably arise from distinct structural forms of
misfolded prion proteins (e.g. distinct three-dimensional
structures and/or chemical modiﬁcations).
Changes in gene expression induced by prion infection were
followed at multiple time points in diverse mouse–prion
combinations over the entire course of the incubation times
with end points ranging from 56 to 392 days (Figure 1 and
Table I: incubation time is deﬁned as the time period from prion
infection to an end point, where all mice in each combination
showedend-stageclinicalsignsofpriondisease(exceptforPrnp-
null(0/0)mice)).Threefactorsresponsibleforthiswiderangein
incubation times are represented in our mouse strain–prion
strain combinations: (1) distinct prion strains can produce
different incubation times in genetically identical hosts, (2) host
genotype determines incubation times for a prion strain with the
allelic forms of the PrP gene (Prnp) having the strongest effect,
and (3) concentrations of PrP affect the incubation times.
Infected animals exhibit no signs of illness over most of their
incubation periods. The dynamically changing DEGs were
mapped onto a series of known protein interaction maps and
integrated with histopathological data on PrP
Sc accumulation
and distribution in the brain at multiple time points during
disease incubation. This integration was used to develop
hypothetical molecular subnetworks presumably encoding
various cellular processes that are perturbed by prion infection
andthesehypotheseswerevalidatedbystatisticalandbiological
assessments of the DEGs central to prion disease. The networks
identify perturbations of cellular processes that appear essential
for prion replication and also the interactions of such processes
with subnetworks involved in pathological changes. With the
exception of the prion replication and accumulation network,
similar changing network processes are seen in other neurode-
generative disorders, including Alzheimer’s disease (Bossy-
Wetzel et al, 2004; Spires and Hannan, 2007).
It is important to stress that dynamic biological networks may
change in two ways—the transcripts of the nodal points in the
network may change in concentration orchemical structure; the
architecture of the network may change in the nature of its
connections or interactions. One of the grand challenges of
systems biology is to develop methods that may easily measure
the dynamically changing architecture of networks—and
currently we are unfortunately forced to map or correlate the
dynamical changes in transcripts, histopathology and clinical
signsonto networks, thedynamics of which are revealed only by
changes in the concentrations of mRNAs. Even with this coarse
granularity of understanding, powerful insights into the nature
of prion disease emerge from the correlation of histopathology,
clinical signs and dynamical networks—explaining much of
what we already know about this disease mechanistically in
terms of biological network behavior as well as beginning to
providing insights into new pathogenic mechanisms and
potential strategies for therapeutic intervention.
Results
Microarray analysis of gene expression
To facilitate the identiﬁcation of differential gene expression
relevanttoessential processesinprionreplication anddisease,
Figure 1 Strategies for identiﬁcation of 333 core differentially expressed genes (DEGs) and their functional analysis in mouse prion diseases. Two prion strains (RML
and 301V) were used for inoculating mice from six different genetic backgrounds (B6, B6.I, FVB, Tg4053, 0/þ, and 0/0) to generate eight prion–mouse combinations.
Fromthelistof7400DEGsidentiﬁedfromatleastoneoftheﬁvecombinationswithnormallevelsofprionprotein(1X),333DEGssharedbyallﬁvewereselectedthrough
novelstatisticalmethodstorepresentperturbednetworksessentialtoprionpathophysiology.Venndiagramshowstheoverlapofthe333DEGswithDEGsfromTg4053-
RML (mice expressing eight times of normal prion protein levels) and from 0/þ-RML (mice expressing one-half of normal prion protein levels). Among 333 DEGs, 161
genes were mapped to networks through protein–protein interaction network or metabolic pathways. Also, by comparison of 333 DEGs with previous prion microarray
studies, we identiﬁed 178 DEGs that have not been reported in connection with prion disease.
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shown in Table I. The combinations reﬂect three different
factors that can dramatically impact the incubation time: prion
strain, host genotype, and PrP concentration. Two prion
strains, Rocky Mountain Lab (RML) mouse-adapted scrapie
prions and 301V mouse-adapted BSE prions, produce drama-
tically different incubation times in a single inbred strain of
mice. For example, C57BL/6J (B6) mice inoculated with RML
(B6-RML) have short incubation times comparedwith B6 mice
inoculated with 301V prions (B6-301V) (see Table I). Host
genotype also affects incubation time (Westaway et al, 1987).
Indeed, alternative alleles of the PrP gene, Prnp, encode
distinct proteins that dramatically alter incubation time.
B6 and B6.I-Prnp
b (B6.I) mice are congenic for the interval
on Chr 2 that contains Prnp (Carlson et al, 1993, 1994).
B6 mice inoculated with RML prions (B6-RML) have short
incubation times, whereas B6.I (Prnp
b) mice inoculated with
the same prion strain (B6.I-RML) have long RML incubation
times owing to their different PrP sequences (Westaway et al,
1987). The converse is true for 301V prions (B6-301Vand B6.I-
301V) with B6.I mice having shorter incubation times than B6
mice (Bruce et al, 1994; Carlson et al, 1994). Thus, it is
important to stressthat long incubation time is not an inherent
property of either Prnp genotype or prion strain, but reﬂects
interactions between the host and the agent.
PrP concentration also affects incubation time. The FVB/
NCr (FVB) genetic background was used for testing effects of
thelevelofPrPexpressionongeneexpressioninpriondisease.
Mice that are heterozygous for a null allele of Prnp, (FVB.129-
Prnp
tm1Zrch FVB)F1(0/þ),expresshalftheamountofPrPas
FVB, and have very long incubation times in spite of
accumulating high levels of PrP
Sc in a long preclinical stage
(Bueler et al, 1994; Manson et al, 1994). On the other hand,
FVB-Tg(PrP-A)4053 mice (Tg4053) that overexpress PrP
transgenes have very short incubation times (Carlson et al,
1994). FVB, 0/þ, and Tg4053 micewere inoculated with RML
prions (FVB-RML, 0/þ-RML, and Tg4053-RML). FVB.129-
Prnp
tm1Zrchmice(0/0)thatlackPrPentirely,cannotbeinfected
with prions (Bueler et al, 1993) and do not develop disease,
were also inoculated with RML prions to eliminate DEGs
induced by prions that are not relevant to prion disease. Only
one statistically signiﬁcant DEG (Itgam) was found in 0/0
mice—reassuring us that the statistics and subtractive
analyses of dynamically changing transcriptomes guided by
prion biology worked effectively.
Thus, the eight mouse strain–prion strain combinations can
be assigned to different groups to emphasize different aspects
of diseaseandtheDEGs generatedbythesegroups canbe used
in subtractivecomparisons toanalyze discreteaspects of prion
disease. Grouping B6-RML, B6-301V, B6.I-RML, B6.I-301V, and
FVB-RML will emphasize DEGs induced by both prion strains
and across incubation times; such shared DEGs are likely to
reﬂect functionally important processes. The combinations
also can be grouped according to prion strain for the
identiﬁcation of DEGs enriched in response to one strain
versus the other (comparing B6-RML, B6.I-RML, and FVB-
RML with B6-301V and B6.I-301V). Short incubation time
combinations reﬂecting prion strain–PrP genotype interac-
tions (B6-RML, B6.I-301V, and FVB-RML) also can be
compared with long incubation time combinations (B6-301V
and B6.I-RML). The genetically modiﬁed combinations (0/þ-
RML and Tg4053-RML) were used as biological ﬁlters whose
incubation time differences reﬂected PrP concentration rather
than PrP genotype.
Comparison of B6 and FVB mice inoculated with RML
(B6-RML and FVB-RML) that do not have a large difference in
prionincubation times servedto ﬁlterout DEGsthat presumably
reﬂect mouse strain genetic polymorphisms (see Supplemen-
tary Figure S1 showing Ccl12, Usp18, and Bst2 as examples of
genes, the expression of which increased only in B6 mice).
Brains from three mice per group were harvested every 1, 2,
or 4 weeks depending on the length of the incubation times as
indicated in Table I (the idea was to have 8–10 sample
comparisons across the incubation period). Comprehensive
time course transcriptomic data sets were generated from each
of the eight mouse strain–prion strain combinations using
Affymetrix mouse array 430 2.0 chips (450 arrays, see
Materials and methods and Supplementary information).
The noise in this enormous amount of data includes both
(1) biological noise due to environment-induced or stochastic
variation among replicate, genetically identical individual
mice that could obscure meaningful, but small, differences
coming from different prion strains, alternative alleles of Prnp,
differences in PrP concentration, and the resulting differences
in incubation time and dynamics of pathological changes and
(2) technological noise from variation in prion inoculation
Table I Mouse strain–prion strain combinations
Mouse strain Prnp genotype Prion strain End point
a (days/weeks) Harvest interval
b (weeks)
C57BL/6J (B6) a/a RML 161/23 2
C57BL/6J (B6) a/a 301V 287/41 4
C57BL/6.I-1 (B6.I) b/b RML 336/48 4
C57BL/6.I-1 (B6.I) b/b 301V 126/18 2
FVB/NCr (FVB) a/a RML 154/22 2
FVB-Tg(PrP-A)4053 (Tg4053) 430a RML 56/8 1
(FVB x FVB.129-Prnp
tm1Zrch)F1 (0/+) a/0 RML 392/56 4
FVB.129-Prnp
tm1Zrch (0/0) 0/0 RML 196/28
c 4
aEnd point is equivalent to the incubation time in this study, which is deﬁned as the interval between prion inoculation to end point. With the exception of 0/0 mice, all
animals were at the terminal stages of disease when killed for brain harvest. For each combination, a set of mice was inoculated with brain homogenate from normal
mice and brains were harvested at the same time points as prion-infected mice.
bBrains fromthreemice were takenat each time point. In a fewinstances, the interval deviatedfromthat shown. Forexample, the ﬁnal interval for B6-RML was 1 week
due to severity of illness in these mice. The actual intervals are indicated in ﬁgures that follow.
cAdditional three RML-inoculated and three normal brain homogenate-inoculated 0/0 mice were aged 357 days (51 weeks).
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analysis, the array measurements themselves, and other
factors. The majority of transcripts do not change their
expression patterns as a result of prion disease, though some
could be associated with prion disease despite no expression
change—Prnp is the best-known example. The transcripts that
are differentially expressed can also show different temporal
patterns dependenton the mousestrain–prion straincombina-
tions. The challenge here is to reliably detect initially small
changes superimposed on a large more constant background.
We developed an effective data analysis framework that can
extract core prion-related signatures from such noise-cor-
rupted data by resolving the noise-related problems. To cancel
out responsescaused byintracerebral inoculation and aging of
the mice, we performed microarray analysis of age- and
genotype-matched control mice inoculated with brain homo-
genates from normal mice at each time point; differential
mRNA expression at each time point in each mouse–prion
combination reﬂected subtraction of expression from the
corresponding control mice. This minimized both biological
and technological noises.
We developed a statistical method that effectively identiﬁed
a core gene set, the expression levels of which were changed
similarly across multiple mouse–prion combinations. The
identiﬁcation of this core gene set reduced the whole genome-
scale data down to a smaller data set with potential prion
disease association. Our method to identify shared expression
patternsbyintegratingmultiplemousestrain–prionstraindata
allowed the detection of differential signals that were marginal
in some individual combinations but signiﬁcant when
considering all combinations together. Although analysis of
DEGs using mRNA prepared from whole brain dilutes
expression signals from individual brain regions, this integra-
tion-based gene selection compensates by its biological focus
on changes that are relevant to the progression of pathology
and prion replication. That is, this method can reliably select
as DEGs the genes with marginal P-values (close to the cutoff)
due to small expression changes (e.g. fold change¼1.5) over
time in the individual mouse–prion combinations by produ-
cing signiﬁcant overall P-values (o10
 3) when the individual
marginal P-values in multiple mouse–prion combinations
were combined (details of the method described below).
Using this method, we found that the overall P-values for such
transcripts tend to be smaller than those of the transcripts that
showed inconsistent temporal expression patterns (e.g.
changed in some combinations and not changed in the others
or changed in opposite directions) across the multiple mouse–
prion combinations.
Shared DEGs in prion disease
To identify genes involved in essential processes related to
prion pathogenesis, we ﬁrst focused on the ﬁve prion strain-
mousestraincombinations(B6-RML,B6.I-301V,B6-301V,B6.I-
RML, and FVB-RML) that reﬂect Prnp allele- and prion strain-
dependent short and long incubation times with normal levels
of prion protein (Figure 1). We developed a novel statistical
method (see Materials and methods and Supplementary
information for further details) to identify the genes that are
differentially expressed and also whose differential expression
patterns are shared in the ﬁve combinations.We identiﬁed 333
DEGs (representing 428 probe sets, overall Po10
 3; see
Supplementary Table S1 for the complete list) with shared
temporal patterns of differential expression in the ﬁve core
mouse–prion combinations. As will be presented later, these
shared DEGs were also evaluated in 0/þ and Tg4053 mice
where long and short incubation times are dependent on PrP
concentration rather than on prion strain–PrP allotype inter-
actions. Proﬁles for the top 20 shared DEGs with the lowest
P-values (highest statistical signiﬁcance for dynamic changes
inpriondisease)andforthebottom20DEGsatornearP¼10
 3
(lowest statistical signiﬁcance) are shown in Figures 2A and B.
These proﬁles illustrate the range and patterns of shared
expression across the ﬁve mouse–prion combinations used to
identify shared transcripts as well as in 0/þ and Tg4053 mice
inoculated with RML. The 333 shared DEGs did not change
their levels in RML-inoculated 0/0 mice—supporting the
contention from other subtractive analyses that these are
reﬂections of the prion disease process.
Many of the highly signiﬁcant DEGs had been identiﬁed in
previous transcriptomic studies on differential gene expres-
sion in prion-diseased mice (Booth et al, 2004; Riemer et al,
2004; Xiang et al, 2004, 2007; Brown et al, 2005; Skinner et al,
2006; Sorensen et al, 2008). Forexample, of the top 20 DEGs in
our study all but two (Iﬁt1 and 0610011I04Rik) had been
identiﬁed previously in at least one mouse strain–prion strain
combination in one or more microarray studies. In contrast, only
9 of the bottom 20 genes of the core 333 gene list were found in
previous studies (Figure 2B). Asterisks on the gene labels in
Figures 2A and B indicate DEGs unique to this study. Overall,
about half—178 of the 333 genes that we classiﬁed as shared—
had not been identiﬁed previously as differentially expressed in
prion-infected mice; only 11 of these were downregulated
(Supplementary Table S1). Microarray data were validated using
RT–PCR for 59 of the 333 shared genes as shown in
Supplementary Figure S2. These shared DEGs were used as the
basisforconstructionofhypotheticaldynamicproteininteraction
networks for integration with pathological changes and PrP
Sc
accumulation throughout the incubation period.
Integration of data from genetically modiﬁed mice
to assess functional signiﬁcance of DEGs
We examined the effects of PrP concentration on differential
expression patterns in prion infection. These data can be
useful, for example, in discriminating DEGs that may be
involved in prion replication from those responsible for
neuron dysfunction and death, and in distinguishing non-
pathogenic responses to PrP
Sc accumulation from those likely
to be responsible for clinical disease. Mice heterozygous for
the null allele of Prnp (0/þ) have very long incubation times.
Although the rate of accumulation of PrP
Sc is slower than that
in wild-type mice, proteinase K-resistant PrP
Sc eventually
reaches levels that are very similar to those in terminal FVB
micewellbeforeanysigns ofdiseaseoccur (Figure3A)(Bueler
et al, 1994; Manson et al, 1994). Even 40 weeks after infection
no clinical signs are apparent in 0/þ mice even though the
level of accumulation and distribution of PrP
Sc is comparable
to that in FVB mice exhibiting signiﬁcant clinical signs
Dynamical prion disease networks
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mice might be more relevant to prion replication and less
pathogenic host responses to PrP
Sc accumulation than to
neurodegeneration and cell death. The dramatic increase in
scrapie survival times of 0/þ mice in spite of carrying similar
amounts of PrP
Sc as seen in terminal wild-type FVB mice for
more than 200 days is an apparent consequence of the lower
steady-state level of PrP
C in the brains of 0/þ mice—about
one-half of that in wild-type mice. Consequently, the rate of
accumulation of PrP
Sc in the brain is signiﬁcantly less than in
wild-type mice as is the rate of accumulation of neurological
damage that ultimately results in clinical signs (see histoblots
in Figure 3A and in the Prion Disease DataBase (PDDB)
website, http://prion.systemsbiology.net).
Among 333 shared DEGs gleaned from ﬁve prion–wild-type
mouse strain combinations, 311 DEGs were changed in 0/þ
mice (Po0.05; Supplementary information). A subset of the
311 DEGs shared by 0/þ were involved in key biological
processes, as identiﬁed by analysis of their Gene Ontology (GO)
annotations. These processes include complement activation,
Figure2 Expressionproﬁlesofgenessharedamongcomparisonofﬁvemouse–prioncombinationsoruniquetoTg4053-RML.Dynamicgeneexpressionproﬁlesinall
eight mouse strain–prion strain combinations are shown for three cases in the order of B6-RML, B6-301V, B6.I-RML, B6.I-301V, FVB-RML, Tg4053-RML, 0/þ-RML,
and 0/0-RML: (A) top 20 genes with highest statistical signiﬁcance for involvement in prion pathology among 333 differentially expressed genes (DEGs) shared by ﬁve
combinations, B6-RML, B6-301V, B6.I-RML, B6.I-301V, and FVB-RML; (B) bottom 20 genes with lowest statistical signiﬁcance for involvement in prion pathology
among 333 shared DEGs; and (C) top 20 DEGs with highest statistical signiﬁcance for involvement in prion pathology among RML-infected Tg4053 mice.
Dynamical prion disease networks
D Hwang et al
& 2009 EMBO and Macmillan Publishers Limited Molecular Systems Biology 2009 5Figure 3 Time course histoblots and proﬁles of selected DEGs in three mouse strains with varying PrP
C concentration. (A) Histoblots are shown for dynamic patterns
ofaccumulationof proteinase K-resistant PrP
Scinbrains ofRML-infected mice withwild-type PrP
Cconcentration (FVB),half of wild-type PrP
C concentration (0/þ), and
approximately eight times of wild-type PrP
C concentration (Tg4053). (B) Expression proﬁles of shared DEGs representing key network modules are shown for FVB,
Tg4053,and0/þ mice.NosigniﬁcantchangesweredetectedforthesegenesinmicelackingthePrnpgene(0/0).Percentageoftheincubationtimes(incubationtimeis
deﬁned in this paper as the time period from prion inoculation to end point) for the time points when gene expression changes start to occur are indicated with arrows in
histoblot series (A) and gene expression proﬁles (B).
Dynamical prion disease networks
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noglycan (GAG) metabolism, and sphingolipid synthesis/
degradation (Figure 3B). These results are consistent with
these genes and their associated processes playing important
roles in PrP
Sc replication and accumulation.
A signiﬁcant question in prion disease is whether glial (both
microglia and astrocytes) activation is triggered by accumula-
tion of PrP
Sc directly or by neurodegenerative changes in
neuronsduetoprionreplication.TheresultsinFigure3Bshow
that genes associated with microglial proliferation and
astrocytosis (Cd14, Cd68, Gfap, and C1qb) are not upregulated
in very long incubation time 0/þ mice until B16 weeks
(B30% of the incubation period) when levels of PrP
Sc were
ﬁrst detectable in histoblots. Increased levels of these glial
mRNAs occurred earlier (12 weeks) but after a greater portion
of the 54% of incubation time had passed in their short
incubation time partner (Figure 3B). The appearance of glial
DEGs in 0/þ mice well before any clinical signs or increase in
the expression of genes indicative of neuronal damage
implicates a direct response to PrP
Sc, though signals from
neurons can be ruled out.
Tg4053 mice have a short interval from inoculation to death
and in conjunction with 0/þ mice could aid in discrimination
of replication and pathogenesis. RML-infected Tg4053 mice
overexpressing PrP showed signiﬁcant changes in 125
(Po0.05 in Tg4053) of the 333 DEGs in the shared set.
Prominent shared DEGs in most of the key shared modules
exhibited similar patterns in Tg4053 mice, though generally
with differentials of smaller magnitude and closer in time to
clinical illness and death than all other combinations of prion
and strain (see Figure 3). Tg4053 mice also showed a set of
highly signiﬁcant DEGs that were not seen in the other
combinations. The 20 DEGs that were most signiﬁcant in
Tg4053 mice along with their expression in the other
combinations are shown in Figure 2C. Unlike 0/þ mice,
Tg4053 mice (that overexpress PrP and die from RML scrapie
at B8 weeks) show increases in a set of glial genes at 6 weeks
(75% of its incubation time; Figure 3B). The difference in
dynamics of such genes is similar to the dynamics of PrP
Sc
increase. Note the points at 16 weeks in 0/þ, 12 weeks in FVB
wild type, and 6 weeks in Tg4053 mice (see the arrows in
Figure3Ahistoblots).Alsowenotedthatthetemporalpatterns
of such genes are similar to those of the genes involved in
androgen/arachidonate metabolism and synaptic upregulated
DEGs. Combining the observations in Figure 3, we conclude
that microglial activation and reactive astrocytic gliosis reﬂect
responses to accumulation of PrP
Sc as well as to early
degenerative changes in neurons, speciﬁcally synapse loss
(Jeffrey et al, 2000; Ishikura et al, 2005). Note that DEGs
associated with neurodegenerativechanges arenot detected in
our whole-brain data until disease is widespread.
Construction of dynamic networks: PrP
Sc
accumulation
Toassociatethegenesshowingdifferentialexpressionpatterns
with fundamental processes, we constructed hypothetical
dynamic networks. Of the 333 shared DEGs, only 173 genes
had sufﬁcient protein–protein interaction or metabolic
pathway information available in the literature for inclusion
in one or more of our networks; 161 of these genes were
included. Among the 161 ‘network’ genes, 117 genes were
mapped to functional modules that have been previously
associated with prion disease, whereas 44 genes were used to
construct six novel functional modules (see Table II for
selected genes for the novel modules; see below for details).
The172genesthatcouldnotbesoincludedhavebeengrouped
according to known functions (114 genes with prion-asso-
ciated functions, 19 genes with novel functions, 27 genes with
predicted functions, and 12 genes with no known functions;
see also Supplementary Table S1 for details and Supplemen-
tary Figure S8 for distribution of the genes in the various
groups) or shared temporal expression patterns (Supplemen-
tary Figure S3). Interestingly, two shared DEGs with unknown
functions (AU020206 and 2310033F14Rik) were identiﬁed
from non-coding regions of the genome. It will be interesting
to characterize their possible regulatory roles, if any, in prion
disease.
To produce comprehensive networks, we relaxed the
stringent P-value cutoff of 10
 3 that was used for shared DEGs
to include more transcripts (Po0.01) showing similar differ-
ential expression patterns in two or more combinations. The
inclusion of such genes allowed us to reconstruct well-
connected networks thus describing a broad range of prion-
related biological processes, which were still represented by
the shared DEGs (Supplementary information). For network
construction, we clustered these genes into four groups
representing four major pathological features of prion disease:
(1) PrP
Sc replication and accumulation, (2) synaptic degenera-
tion, (3) microglial and astrocyte activation, and (4) neuronal
cell death. This was done by GO clustering of the genes using
FuncAssociate (Berriz et al, 2003) and then assigning the GO
clusters to one or more of the four pathological feature groups,
based on relationships between the corresponding GO terms
and four pathological features (Supplementary Table S2 and
Supplementary Figure S4). For example, GO clusters of
chemotaxis and complement activation were assigned to
microglial and astrocyte activation. When the relationships
werenotobvious,suchGOclusterswereassignedtoallgroups
of pathological features in which the GO processes can be
possibly involved. For example, complement activation was
assigned to both PrP
Sc replication and accumulation and
microglial and astrocyte activation. Using the proteins
encoded by selected genes assigned to each pathological
group and their nearest interacting proteins, we constructed a
hypothetical protein network describing the interactions in
prion-related biological processes representing each patholo-
gical feature and their dynamic transitions. The interactions
among the network nodes were obtained from the interaction
databases, BIND (http://www.bind.ca) and HPRD (http://
hprd.org). The network nodes were localized according to GO
subcellular component information (lysosome, ER, PM, ECM,
and so on), and the cell types (neuron, oligodendrocyte,
microglia, or astrocyte) were assigned according to informa-
tion from literature and public databases. Strikingly, assign-
ment of cell types for 128 selected DEGs veriﬁed by cell type-
speciﬁc patterns from in situ hybridization data of B6 mouse
brains and image-based informatics annotation (for detailed
methods, see Lein et al, 2007—describing the Allen Brain
Dynamical prion disease networks
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assignments in our hypothetical networks (Supplementary
Table S5). Some of the nodes and modules were assigned to
microglia/astrocytes as these two cell types share gene
expression of major components involved in immune
responses (e.g. complement, TLRs, and cytokines). The
Table II Novel functions represented by selected genes from 333 DEGs (differentially expressed genes) shared by ﬁve mouse–prion combinations
Category Gene
symbol
a
Description Entrez
ID
Previous
studies
b
Human
orthologs
c
Leukocyte extravasation Csf1* Colony-stimulating factor 1 (macrophage) 12977 CSF1
Prg1* Proteoglycan 1, secretory granule 19073 SRGN
Selpl* Selectin, platelet (p-selectin) ligand 20345 SELPLG
Cyba Cytochrome b-245, alpha polypeptide 13057 R, X4 CYBA
Itgax Integrin alpha X 16411 R, X4 ITGAX
Msn Moesin 17698 R, X4 MSN
Androgen metabolism Cyp7b1* Cytochrome P450, family 7, subfamily b, polypeptide 1 13123 CYP7B1
Hsd3b7* Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and
steroid delta-isomerase 7
101502 HSD3B7
Slco2b1* Solute carrier organic anion transporter family, member 2b1 101488 SLCO2B1
Bzrp Benzodiazepine receptor, peripheral 12257 X TSPO
Dbi Diazepam-binding inhibitor 13167 S, Sk, Bo DBI
Iron homeostasis and heme
metabolism
Cp* Ceruloplasmin 12870 CP
Hfe* Hemochromatosis 15216 HFE
Slc39a14* Solute carrier family 39 (zinc transporter), member 14 213053 SLC39A14
Ftl1 Ferritin light chain 1 14325 Sk FTL
Trf Transferrin 22041 Sk, Bo TF
Demyelination, neurogenesis,
axonal transport, ion channels
Kif5c* Kinesin family member 5C 16574 KIF5C
Lgi4* Leucine-rich repeat LGI family, member 4 243914 LGI4
Nupr1* Nuclear protein 1 56312 NUPR1
P2rx7* Purinergic receptor P2X, ligand-gated ion channel, 7 18439 P2RX7
Scn1a* Sodium channel, voltage-gated, type I, alpha 20265 SCN1A
Arachidonate/phospholipid
metabolism and calcium
signaling pathway
Alox5ap* Arachidonate 5-lipoxygenase-activating protein 11690 ALOX5AP
Cyp4f14* Cytochrome P450, family 4, subfamily f, polypeptide 14 64385 CYP4F2
Ptgs1* Prostaglandin-endoperoxide synthase 1 19224 PTGS1
Hpgd Hydroxyprostaglandin dehydrogenase 15 (NAD) 15446 Bo, R HPGD
Plce1* Phospholipase C, epsilon 1 74055 PLCE1
Adcy7* Adenylate cyclase 7 11513 ADCY7
Hematopoiesis Gmfg* Glia maturation factor, gamma 63986 GMFG
Inpp5d Inositol polyphosphate-5-phosphatase D 16331 X INPP5D
Lcp1 Lymphocyte cytosolic protein 1 18826 X4 LCP1
Lpxn Leupaxin 107321 X LPXN
Nckap1l NCK-associated protein 1 like 105855 X NCKAP1L
Old gene symbols
d Updated
gene symbol
Description Entrez
ID
Bzrp Tspo Translocator protein 12257
Prg1 Srgn Serglycin 19073
Selpl Selplg Selectin, platelet (p-selectin) ligand 20345
aGenes with asterisk are unique DEGs to this study; genes in bold and italic show decreased expression in infected mouse brains.
bS (Sorensen et al, 2008); X (Xiang et al, 2007); Sk (Skinner et al, 2006); Br (Brown et al, 2005); Bo (Booth et al, 2004); R (Riemer et al, 2004); X4 (Xiang et al, 2004).
cOrthologous human gene symbols are current as of 28 August 2008.
dGene symbols have been updated in the EntrezGene database as of 28 August 2008.
Figure 4 Dynamic PrP replication and accumulation network. Hypothetical networks of proteins and metabolites that are potentially involved in PrP replication and
accumulation were constructed starting from the list of 333 shared DEGs and protein–protein interaction/metabolic pathway information from public databases. Relative
changes of the transcripts for the corresponding proteins are represented incolor changes: red—upregulation, green—downregulation, yellow—no change. Data for the
transcriptional changes are from BL6 mice infected with RML prions, at 6 weeks (A), 10 weeks (B), 14 weeks (C), 18 weeks (D), 20 weeks (E), and 22 weeks (F) after
inoculation. See main text for detailed description of modules 1 through 6. Ch: cholesterol; ECM: extracellular matrix; PM: plasma membrane. Large nodes indicate
DEGs whose expression change patterns are shared by ﬁve prion–mouse combinations (B6-RML, B6-301V, B6.I-RML, B6.I-301V, and FVB-RML); asterisks indicate
DEGs whose prion-related changes are unique in this study; genes in blue are also DEGs in RML-infected 0/þ mice; genes in bold are also DEGs in RML-infected
Tg4053 mice; genes with solid underline were changed only in mice with short incubation times; genes with dotted underline were changed only in RML-infected mice.
Source data is available for this ﬁgure at www.nature.com/msb.
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(green) in the expression of the corresponding genes at each
time point in B6 mice inoculated with RML. The nodes were
then clustered into functional network modules based on the
similarity in their GO biological processes and their connec-
tivity (Hwang et al, 2005) (see Supplementary Table S2 for
details). The arrows representing metabolic and signaling
pathwayswerealsoaddedbasedontheKEGGpathways.Asan
example, a network of interacting proteins hypothesized to be
involved in prion replication or responses to PrP
Sc accumula-
tion is presented in Figure 4 with the dynamic changes in gene
expressioninB6-RMLshownat6,10,14,18,20,and22weeks.
The highly signiﬁcant (Po10
 3) DEGs are indicated by larger
sized nodes, and DEGs unique to this study are indicated by
asterisks. The underlined nodes represent the genes upregu-
lated only in mice with short incubation times, and the dotted-
underlined nodes represent the genes differentially expressed
only in mice infected by RML prions. A histoblot showing
distribution of proteinase K-resistant PrP
Sc in coronal sections
including the hippocampal formation (approximately Bregma
 1.5 to  2.2mm) is included in each time point panel along
with notation of clinical signs. All data collected in this study
are available online (http://prion.systemsbiology.net/). It is
important to emphasize that the networks discussed here are
hypothetical and construction of alternatives using other
methods is encouraged.
Thenetworktransitionsshowthatdynamicperturbationsof
gene expression associated with biological processes occur in
a speciﬁc order, which independently veriﬁes the conclusion
that neuropathological changes proceed in a stereotypical set
of steps (Bouzamondo-Bernstein et al, 2004). Among the ﬁrst
detectable expression changes (10 weeks) were increases in
mRNA levels of C1qa/b and C3ar1 reﬂecting activation of
microglia and astrocytes, one of the earliest detectable
responses to prion infection (Klein et al, 2001) (Figure 4B,
module 1). Around the same time, the increased activities
of lysosomal proteases were suggested by elevation of the
lysosomalproteasegeneCtsc(Figure4B,module2):lysosomal
proteases may have a role in degradation as well as formation
of PrP
Sc (Zhang et al, 2003). Changes within the lysosomal
module became more obvious at later time points (Figure 4C,
module 2). The network also shows dysregulation associated
with the synthesis, trafﬁcking, and processing of cholesterol
and sphingomyelin, two of the majorcomponents of lipid rafts
where the initial steps of PrP
Sc replication are thought to occur
(Simons and Ehehalt, 2002). At 10 weeks, changes were
detected in the expression of genes controlling trafﬁcking and
conversion of cholesterol (Figure 4B, module 3) and sphingo-
myelin (Figure 4B, module 4) (Rodriguez-Agudo et al, 2008).
At 14 weeks, expression levels of cholesterol synthesis genes,
such as Mvk and Mvd, were decreased, but expression of the
cholesterol transporters or acceptors including Abca1, A2m,
and Apod were increased (see the arrows in Figure 4C, module
5). As will be discussed later, decreases in the expression of
genes involved in cholesterol biosynthesis are particularly
pronounced in mice infected with the RML prion strain.
Changes in sphingolipid metabolism, potentially leading to
a decrease in galactosylceramide, which is found in PrP
Sc
deposits (Klein et al, 1998), are evident by 18 weeks
(Figure 4D, module 4). The network also shows an increase
in GAG metabolism, indicated by increased Gusb and Hexb
mRNA levels, ﬁrst detectable at 14 weeks (Figure 4C, module 6)
(Mayer-Sonnenfeld et al, 2005). This dynamic coupling of
cholesterol, GAG, and sphingolipid pathways with PrP
Sc
suggests, together with the ﬁndings from previous studies,
that prion replication requires the close physical association
amongPrP
C/PrP
Sc,GAG,cholesterol,andsphingolipidonlipid
rafts in the plasma membrane and during trafﬁcking to the
lysosome and endosome (Hijazi et al, 2005; Horonchik et al,
2005). Novel therapeutic approaches for prion disease can be
developed that target these components simultaneously (see
Discussion for details).
Dynamic network describing microglial/astrocytic
activation
Similar to most infectious agents, PrP
Sc induces inﬂammatory
responses by activating innate immunity through glial cells
(microglia and astrocytes) in the brain (Perry et al, 2002;
Sorensenetal,2008).Weconstructedaproteinnetworkmodel
using the shared DEGs that are associated with microglial/
astrocytic activation (Figure 5). This is consistent with
neuropathological data showing that microglia are among
the earliest responders to any form of neurodegeneration
(Rezaie and Lantos, 2001; Wojtera et al, 2005), that microglia
proliferate and hypertrophy in prion disease in response to
deposition of PrP
Sc (Williams et al, 1997), and that reactive
astrocytic gliosis, which tends to follow activation of micro-
glia, is induced by factors released from microglia (Jensen
et al, 1994; Ohno et al, 1995; Nakamura, 2002; Panickar and
Norenberg, 2005). Transcriptome analysis suggests that the
ﬁrst apparent reactive changes (from 10 weeks in B6-RML) are
activation of complement pathwaysbyPrP
Sc (Klein et al, 2001;
Sim et al, 2007; Figure 5, module A), pattern recognition
receptors (PRRs), and other receptors potentially responsible
for PrP
Sc recognition and uptake (Figure 5, module B). Lack of
increased expression of innate immune system genes in 0/þ
mice before 16–18 weeks is compatible with gliosis and
expression of these genes in glia rather than neurons as it
appears that little neuronal damage is seen at this stage
(Figure 5). Similarly, the kinetics of expression of innate
immune receptors and their downstream cytokines relative to
PrP
Scaccumulationsuggestthatthesereceptorsmayrecognize
proteins perturbed by prion infection, such as intraneuronal
proteins and peptides released as a result of early synaptic
changes, rather than carbohydrate moieties on PrP
Sc. Comple-
ment complexes and PRRs may be responsible for stimulating
theproductionof cytokines,chemokines (Figure5,moduleC),
and growth factors (Figure 5, module D), as well as for
astrocytic activation as indicated by increased expression of
glial markers such as Gfap and P2RY receptors (Wang et al,
2005; Figure 5, module E). Activation of endothelial cells
through cytokines released from microglia and astrocytes
would enhance migration of leukocytes from the blood and
their differentiation into microglia (Figure 5, module F). This
possibility is supported by the increased expression of genes
involvedinthemultistepprocessesofleukocyteextravasation:
selectin ligands, adhesion molecules, chemokines and their
receptors, integrins, transendothelial migration genes, and
intracellular signaling molecules. Conversion of mononuclear
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the brain is suggested by upregulation of Csf1 (Figure 5,
module D). Most of these DEGs were shared by 0/þ-RML
mice, thus implying their potential importance in PrP
Sc
replication, but indicating that these responses on their own
are insufﬁcient for the production of clinical signs. Although
this might reﬂect a response to more rapidly accumulating
PrP
Sc, recruitment of microglial cells from blood also might
facilitate PrP
Sc replication by increasing PrP
Sc trapping.
Networks highlighting neurodegeneration and cell death
were also constructed and are presented and discussed as
Supplementary Figures S5 and S6 and are presented on the
PDDB website.
Novel network modules
Our strategy identiﬁed many shared genes not previously
associated with prion disease. Examining the recent literature
for metabolic pathways in which these genes are involved, in
conjunction with the similarity of their expression proﬁles, led
us to hypothesize several novel modules with concerted
changes of expression for closely related genes. The androgen
metabolism module is illustrated in Figure 6A. To our
knowledge, this is the ﬁrst report of potential involvement of
androgen metabolism in prion disease. BZRP (translocator
protein, 18kDa) functions as an essential rate-limiting step
toward mitochondrial biosynthesis of androgenic molecules,
together with its endogenous ligand diazepam-binding in-
hibitor (Dbi) (Papadopoulos and Brown, 1995; Papadopoulos
et al, 2006). The global stimulation of androgen biosynthesis
pathway implies altered levels of neurosteroids in prion
disease. In addition, the increased expression of Cntf as shown
hereandinapreviousstudy(Naetal,2007)maysuggestalink
between perturbed androgen metabolism and glial activation
in prion-infected brains as Cntf upregulation leads to reactive
astrogliosis through the JAK/STAT pathway. A possible
Figure 5 Microglial and astrocyte activation network. Hypothetical networks of proteins and metabolites that are potentially involved in activation of microglia and
astrocytes were constructed starting from the list of 333 shared DEGs and protein–protein interaction information from public databases. Modules A–F denote distinct
functional modules within the network: (A) Complement activation, (B) pattern recognition receptors, (C) cytokines and chemokines, (D) growth factors, (E) reactive
astrogliosis, and (F) leukocyte extravasation. Relative changes of the transcripts for the corresponding proteins are represented in color changes: red—upregulation,
green—downregulation, yellow—no change. Data for differential expression are from BL6 mice infected with RML prions. The temporal expression changes at six time
points (10, 14, 16, 18, 20, and 22 weeks) are represented by the circular heatmaps of the network nodes: the center color of each node indicates the differential
expression at 10 weeks, while the outer circle colors represent expression changes at increasing time points. Large nodes indicate DEGs whose expression change
patterns are shared by ﬁve prion-mouse combinations; asterisks indicate DEGs whose prion-related changes are unique in this study; genes in blue are also DEGs in
RML-infected 0/þ mice; genes in bold are also DEGs in RML-infected Tg4053 mice; genes with solid underline were changed only in mice with short incubation times.
Source data is available for this ﬁgure at www.nature.com/msb.
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receptor has recently been reported (Wang et al, 2008).
CKLFSF3 interacts directly with BLNK (Imamura et al, 2004),
further suggesting a tie between androgen metabolism and
glial activation (see Figure 5, module E). The temporal
patterns of these genes were similar to those in cholesterol
clearance (Figure 3B and Figures 4D–F, module 3), implying
that dysregulated cholesterol metabolism also may be coupled
to the perturbation of neurosteroid metabolism.
A second modulewith potential importance in prion disease
involves iron homeostasis and heme metabolism. Concurrent
upregulation was detected for genes involved in iron uptake,
transport, storage, and heme degradation (Figure 6B). These
results are consistent with two recent in vivo observations:
(1) increased levels of redox-active iron in scrapie-infected
mouse brain (Kim et al, 2000; Basu et al, 2007) and (2) a
stimulatory effect of redox iron on the conversion of PrP
C to
PrP
Sc (Basu et al, 2007). The activation of the heme
degradation pathway in the brain has been associated with
cellular responseto oxidativestress(Barananoet al, 2002).Six
DEGs (Mgst1, Mt1, Mt2, Prdx6, Scara3, and Ucp2) with
protective functions against oxidative stress showed patterns
of expression similar to those of iron heme metabolism genes,
suggesting interaction between the two modules (data not
shown). Iron homeostasis is essential for the maintenance of
oligodendrocytes and myelin in brain (Connor and Menzies,
1996; Ortiz et al, 2004),and its dysregulation may be relatedto
demyelination in prion disease (Walis et al, 2004; Baumann
et al, 2007). Indeed, our data show signiﬁcant changes in the
expressionof genes encoding proteins involved in myelination
(Padi2, AI838057/Met, and Nupr1 (Plant et al, 2006; Moscar-
ello et al, 2007; Ohya et al, 2007).
A third module of interest from our data is arachidonate/
prostaglandin metabolism, in conjunction with phospholipid
metabolism and calcium signaling pathway. Shared DEGs that
are involved in biosynthesis of proinﬂammatory prostaglandins
Figure6 Novelfunctionalmoduleswithdynamicgeneexpressionchangespotentiallylinkedtoprionpathophysiology:(A)androgenmetabolism,(B)ironmetabolism,
(C) arachidonate/phospholipid metabolism. Hypothetical networks of proteins and metabolites that are potentially involved in three novel functional modules were
constructed based on genes selected from the list of 333 shared DEGs and metabolic pathway information from literature. The temporal expression changes at six time
points (10, 14, 16, 18, 20, and 22 weeks after inoculating BL6 mice with RML prions) are represented by the circular heatmaps of the network nodes: the center color of
eachnodeindicatesthedifferentialexpressionat10weeks,whereastheoutercirclecolorsrepresentexpressionchangesatincreasingtimepoints.Largenodesindicate
DEGs whose expression change patterns are shared by ﬁve mouse-prion combinations; asterisks indicate DEGs whose prion-related changes are unique in this study.
See text for detailed description of the three pathways.
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Category Gene symbol
a Description Entrez
ID
Previous
studies
b
Human
orthologs
c
Protection against
oxidative stress
Naprt1* Nicotinate phosphoribosyltransferase domain
containing 1
223646 NAPRT1
Arachidonate/phospholipid
metabolism
Bmp2k* BMP2-inducible kinase 140780 BMP2K
E030018N11Rik* RIKEN cDNA E030018N11 gene 319622 ITPRIPL2
Hematopoiesis Pbxip1* Pre-B-cell leukemia transcription factor interacting
protein 1
229534 PBXIP1
Chondrogenesis Loh11cr2a* Loss of heterozygosity, 11, chromosomal region 2,
gene A homolog (human)
67776 VWA5A
Complement system
(coagulation)
Pp11r* Placental protein 11 related 19011 P11
BC032204 cDNA sequence BC032204 108101 X, X4 FERMT3
Interferon-related Aldh1l2* Aldehyde dehydrogenase 1 family, member L2 216188 ALDH1L2
D12Ertd647e* DNA segment, Chr 12, ERATO Doi 647, expressed 52668 NA
Plscr2* Phospholipid scramblase 2 18828 PLSCR2
Other immune
response genes
4632428N05Rik* RIKEN cDNA 4632428N05 gene 74048 C10orf54
Stno* Strawberry notch homolog (Drosophila) 216161 SBNO2
Gp49a Glycoprotein 49 A 14727 X, R NA
Metal ion binding Antxr1* Anthrax toxin receptor 1 69538 ANTXR1
Dtx3l* Deltex 3-like (Drosophila) 209200 DTX3L
Eya4* Eyes absent 4 homolog (Drosophila) 14051 EYA4
Membrane trafﬁcking Crispld2* Cysteine-rich secretory protein LCCL
domain containing 2
78892 CRISPLD2
Signal transduction 4933428I03Rik* RIKEN cDNA 4933428I03 gene 66775 PTPLAD2
Nucleic acid binding Scrg1 Scrapie responsive gene 1 20284 DD SCRG1
DNA damage repair Parp12* Poly (ADP-ribose) polymerase family, member 12 243771 PARP12
Guanylate binding Mpa2l* Macrophage activation 2 like 100702 NA
Neurological
disorder related
0610011I04Rik* RIKEN cDNA 0610011I04 gene 66058 TMEM176A
1810009M01Rik* RIKEN cDNA 1810009M01 gene 65963 TMEM176B
Phyhd1* Phytanoyl-CoA dioxygenase domain containing 1 227696 PHYHD1
Non-coding genes AU020206 Expressed sequence AU020206 101757 X4 NA
2310033F14Rik* RIKEN cDNA 2310033F14 gene 69555 NA
No predicted functions 1810059G22Rik* RIKEN cDNA 1810059G22 gene 67706 TMEM179B
2310014H01Rik* RIKEN cDNA 2310014H01 gene 76448 KIAA1949
4933411K20Rik* RIKEN cDNA 4933411K20 gene 66756 KIAA1430
9230105E10Rik* RIKEN full-length enriched library, clone:
A130050C20 product
245575 NA
A530050D06Rik* RIKEN cDNA A530050D06 gene 104816 LOC374569
AI452102* Expressed sequence AI452102 330594 NA
E230029C05Rik* RIKEN cDNA E230029C05 gene 319711 NA
2810459M11Rik RIKEN cDNA 2810459M11 gene 72792 X C2orf72
BC025600 cDNA sequence BC025600 231633 X, Sk TMEM119
X99384 cDNA sequence X99384 27355 X KIAA1274
Old gene symbols
d Updated
gene symbol
Description Entrez
ID
Comments
0610011I04Rik Tmem176a Transmembrane protein 176A 66058
1810009M01Rik Tmem176b Transmembrane protein 176B 65963
1810059G22Rik Tmem179b Transmembrane protein 179B 67706
4933428I03Rik Ptplad2 Protein tyrosine phosphatase-like A domain
containing 2
66775
AI452102 E230029C05Rik RIKEN cDNA E230029C05 gene 330594 New GeneID:
319711
BC025600 Tmem119 Transmembrane protein 119 231633
BC032204 Fermt3 Fermitin family homolog 3 108101
Cklfsf6 Cmtm6 CKLF-like MARVEL transmembrane domain
containing 6
67213
Loh11cr2a Vwa5a von Willebrand factor A domain containing 5A 67776
Stno Sbno2 Strawberry notch homolog 2 216161
aGenes with asterisk are unique DEGs to this study; gene in bold and italic shows decreased expression in infected mouse brains.
bX (Xiang et al, 2007); Sk (Skinner et al, 2006); R (Riemer et al, 2004); X4 (Xiang et al, 2004); DD (Dandoy-Dron et al, 1998).
cOrthologous human gene symbols are current as of 28 August 2008. Those denoted as ‘NA’ do not have ofﬁcial orthologous human genes.
dGene symbols of the following 10 genes have been updated in the EntrezGene database as of 28 August 2008.
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show shared patterns of increased expression (Figure 6C).
Activation ofthismodule shouldpromptasearchforexcessive
production of these pro-inﬂammatory metabolites in prion-
infected brains (Kikuta et al, 2000). Interestingly, upregulation
of COX-1 (Ptgs1) has been observed in post-mortem brains of
CJD patients (Deininger et al, 2003). Moreover, it was recently
shown that coactosin-like 1 (Cotl1) can also upregulate ALOX5
(5-lipoxygenase) activity and LTA4 production in a Ca
2þ-
dependent manner (Rakonjac et al, 2006). Changes in
arachidonate metabolism may be linked with the perturbation
of phosphatidylinositol metabolism and calcium signaling
pathway through AMP deaminase (Figure 6C).
Five additional processes (demyelination-neurogenesis,
hematopoiesis, chondrogenesis, DNA damage repair, and
uracil/thymidine catabolism), representedby20 sharedDEGs,
may also be associated with prion disease (see Table II for
selected modules and genes and Supplementary Table S1 for
the complete list). In addition, among 39 DEGs with no known
functions, 27 genes can be potentially related to various
functional modules mentioned above through predictions
using protein domain information or indirect experimental
evidence (for example, E030018N11Rik is predicted to be
involved in phospholipid metabolism because of its protein
sequence similarity to ITPRIP family, including inositol 1,4,5-
triphosphate receptor interacting protein; see Table III for
truncated list of predicted functions and associated genes and
Supplementary Table S1 for the complete list).
In short, novel associations revealed in our study can be
used to generate testable hypotheses for events in prion
disease.Searchingforassociationsamongsubgroupsofmouse
strain–prion strain combinations is also worthwhile. The
complete list of functional modules enriched with 333 shared
DEGs is shown in Supplementary Table S1.
Incubation time- and prion strain-associated DEGs
Grouping mice according to differences in incubation times
amongtheﬁvecoreprion–mousecombinationsthatwereused
to deﬁne shared DEGs identiﬁed 55 genes, the expression of
which was signiﬁcantly increased (Po10
 4) in the three short
incubation time combinations (B6-RML, B6.I-301V, and FVB-
RML) but showed no signiﬁcant change in mice with long
incubation times (B6-301V and B6.I-RML). Statistical meth-
odologiesforgroupingDEGsbyincubationtimeorprionstrain
are provided in Supplementary information. Examples are
shown in Figure 7. In total, 27 of these short incubation time
DEGs showed increased expression in scrapie-infected mice
and 28 were downregulated (Supplementary Table S3). There
were no genes that were differentially expressed only in the
long incubation time combinations. It is important to stress
thatalongincubationtimeinitselfdoesnot precludedetecting
differential expression of the short incubation time DEGs.
RML-infected 0/þ mice, which have very long incubation
times, show signiﬁcant scrapie-induced changes in 5 of the 55
‘short incubation time’ DEGs (Po0.05 in 0/þ-RML). Among
Figure 7 Expression proﬁles of DEGs changing predominantly in three short incubation time combinations or in two RML-infected mice. (A) Top 10 genes that show
selective changes in short incubation time combinations, B6-RML, B6.I-301V, and FVB-RML as compared with long incubation time combinations (B6-301V and B6.I-
RML). The changes of these genes in 0/þ is also shown as another example of mouse–prion combination with long incubation time; (B) top 10 genes that show
selective changes in RML-infected combinations, B6-RML and B6.I-RML as compared with 301V-infected combinations, B6-301V and B6.I-301V.
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tiontimecombinations,wefounddecreasedexpressionoffour
genes (Cycs, Ndufa10, Cox6b1, and Atp5j2) involved in ATP
biosynthesis in the oxidative phosphorylation pathway (Sup-
plementary Figure S7A), and increased expression of ﬁve
genes (Chst2, Ndst1, Sdc3, Sulf2, and Galnt6) that mediate
biosynthesis of various GAGs (Figure 4, see also Supplemen-
tary Figure S7B). The increased levels of Ndst1 and Sulf2 and
decreased expression of Hs6st2, whose protein catalyzes the
6-O-sulfationofheparansulfates(afunctionoppositetothatof
SULF2) may redirect metabolic ﬂux to 2-O-sulfated heparan
sulfate, an entry point to the GAG degradation pathway (Pikas
et al, 1998). This ﬁnding is consistent with the potential roles
of GAG in prion pathology as membrane receptors for PrP
Sc as
noted earlier and is supported by the effect of drugs interfering
with PrP
Sc–GAG interactions, such as Tilorone (Mayer-
Sonnenfeld et al, 2008) and Copaxone (Engelstein et al,
2007) on increasing the incubation time of prion disease. It is
important to stress that the differences betweenshort and long
incubation time DEGs are not absolute, but rather quantitative
differences in expression between the two groups. Thus, our
data suggest that perturbation of mitochondrial ATP synthesis
and lysosomal GAG biosynthesis are two important factors
that can contribute to acceleratedprogression of prion disease.
We also found that the remaining 55 short incubation time
DEGs are involved in various signaling pathways such as
calcium signaling (e.g. Camk4), phosphatidylinositol signal-
ing (e.g. Itpr1), and MAPK signaling pathways (e.g. Ptprr)a s
well as in adhesion (e.g. Pvrl3), axon guidance (e.g. Ntng1),
and apoptosis (e.g. Cﬂar).
Grouping the B6 and B6.I congenic strains according to
prion strain identiﬁed 39 DEGs that were signiﬁcant only in
RML inoculated mice. In total, 19 of these genes were elevated
and 20 showed decreased expression. These genes are
indicated in Supplementary Table S4 and Figure 7. No DEGs
were found that were speciﬁc to 301V inoculated mice.
Interestingly, 7 of the 20 genes with decreased expression
(Hmgcs1, Nsdhl, Cyp51, Sc4mol, Idi1, Sc5d and Sqle)a r e
involved in cholesterol biosynthesis, showing consistent
reduction in RML-infected mice but no signiﬁcant changes in
301V-infected mice (Figure 4, module 3). Four of these genes,
Cyp51, Sc4mol, Nsdhl, and Sqle show similar expression
patterns in normal B6 mouse brain as assessed using the
NeuroBlast function of the Allen Brain Atlas (Lein et al, 2007).
Thecorrelationindistributionamongthefourwasparticularly
strong in the thalamus (for coronal sections, correlation
coefﬁcients with Cyp51 for Sqle¼0.85, for Sc4mol¼0.76, and
for Nsdhl¼0.81).
Discussion
Our goal in using whole-brain mRNA expression data from
diverse mouse strain–prion strain combinations as the core of
a systems analysis of prion disease was to identify and assign
function to interacting networks involved in prion replication
and pathogenesis. The earliest detectable neuropathological
events following intracerebral inoculation with prions are
conversion of PrP
C to PrP
Sc in neuronal membranes, axonal
transport of PrP
Sc to adjacent neurons, accumulation of PrP
Sc
in axon terminals, and transynaptic spread of PrP
Sc formation
in the plasma membrane of the postsynaptic neurons.
Accumulation of PrP
Sc in synaptosomes is followed within a
week by abnormal distribution of synaptic vesicles in
presynaptic boutons, decreased evoked release of neurotrans-
mittersbysynaptosomes (Bouzamondo-Bernstein et al, 2004),
presynaptic bouton degeneration and both atrophy and loss of
dendrites (Ishikura et al, 2005). These neurodegenerative
events can be highly localized early in disease, but, in
combination with the resulting release of PrP
Sc into the
extracellularspace diseased cells appear to attract and activate
microglia, the ﬁrst responders to neurodegeneration (Rezaie
and Lantos, 2001). Activated microglia may be a major factor
causing nerve death in prion diseases (Giese et al, 1998; Priller
et al, 2006). Although the mechanism of microglial-mediated
nerve cell death is not fully understood, one possibility is
overactivation of microglia secondary to exposure to PrP
Sc
(Block et al, 2007).
The mechanism of nerve cell death is unknown; however,
multiple pathogenic mechanisms have been proposed, includ-
ing: (1) deafferentiation secondary to extensive axon terminal
degeneration (Brown et al, 1997; Brown, 2001); (2) decreased
binding afﬁnity of receptors for neurotransmitters and trophic
factors required for neuronal viability secondary to accumula-
tion of large amounts of PrP
Sc in neuronal plasma membranes
(Kristensson et al, 1993; Veyet al, 1996; Wong et al, 1996); and
(3) selective degeneration of GABAergic inhibitory inputs to
neurons leading to excitatory neurotoxic nerve cell death
(Guentchev et al, 1997, 1998, 1999). Of these putative
mechanisms, the continuous conversion of PrP
C to PrP
Sc in
cholesterol-rich membrane rafts followed by continuous
endocytosis and accumulation of large amounts of protease-
resistant PrP
Sc in lysosomes when large numbers of neurons
degenerate (Bouzamondo et al, 2000; Bouzamondo-Bernstein
et al, 2004) most likely accounts for a signiﬁcant amount of
nerve cell death. However, these putative causes of neuronal
death are not mutually exclusive and, indeed, may all
contribute to late stage nerve cell death both in prion disease
acquired by infection with prions and spontaneous (sporadic)
and familial prion disease.
What does this brief review of our understanding of
neurodegeneration in CJD and scrapie tell us? First, neurode-
generation proceeds in a stereotypical set of steps from
accumulation of PrP
Sc in cholesterol-rich lipid rafts to early
synapse degeneration to nerve cell death. Second, the data
supporting such degeneration sequence are derived from
research in multiple laboratories that have viewed neurode-
generation in prion diseases from different perspectives and
with different preconceptions about neurodegeneration in
prion disease. Our comprehensive and independent systems
analysis provides gene expression that correlates very well
with pathological information in the whole-brain studies of
priondiseaseandmayaidinorganizingthecurrentabundance
of data fragments into a coherent pathogenic model of
neurodegeneration. The meshing of our networks constructed
using transcriptome data with deﬁned pathological processes
increases our conﬁdence that systems analyses provide a valid
tool for hypothesis development.
The most important feature of the dynamic networks is that
the transitions in gene expression precede clinical signs and
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Sc accumulation. For example, perturbations of several
network modules, such as complement activation (Figure 4,
module 1), lysosomal protease activity (Figure 4, module 2),
and GAG metabolism (Figure 4, module 6) are evident earlier
thantheclinicalsignsandwidespreadPrP
Scaccumulation.Itis
also important to stress that changes reﬂecting early synaptic
loss that is ﬁrst detectable histologically in the thalamus are
not detected until later in mRNA prepared from whole brain
due to signal dilution. The dynamic changes in each of these
perturbed network modules precede, but track perfectly with,
clinical signs and PrP
Sc accumulation, indicating that the
perturbations of biological processes in the network modules
are potential contributors to PrP
Sc accumulation and the
resulting clinical signs. It should be noted that virtually all
neuropathological, pathophysiological and clinical data to
date have been correlated with protease-resistant rPrP
Sc and
have not taken into account protease-sensitive sPrP
Sc. In the
earlystagesofinfectionofmicewith prions,B80%ofthetotal
PrP
Sc is sPrP
Sc (Safaret al, 2005). AtB60 days postinoculation
(d.p.i.) when early occurring dendritic atrophy begins, about
twice as much sPrP
Sc is found in the brain than rPrP
Sc.
Whether or not sPrP
Sc perturbs biological processes presented
in our hypothetical protein networks remains to be deter-
mined.
Examination of co-expression patterns can lead to develop-
ment of testable hypotheses for networks important for prion
pathogenesis. Our results suggest that delay or inhibition of
prion replication and accumulation might be achieved by
targeting some combinations of cholesterol homeostasis, GAG
metabolism, and/or sphingolipid metabolism (Figure 4).
Several drugs can inhibit prion replication, all of which target
a biological process involved in one of these three network
modules: (1) GAG depletion (chlorate, heparinase III) (Gabi-
zon et al, 1993; Ben-Zaken et al, 2003); (2) inhibition of GAG’s
binding to PrP
C (quinacrine) (Mayer-Sonnenfeld et al, 2008);
(3) disruption of lipid rafts through cholesterol redistribution
(quinacrine) (Klingenstein et al, 2006) and (4) inhibition of
cholesterol biosynthesis (desipramine) (Klingenstein et al,
2006). However, our systems approach that builds hypothe-
tical dynamic relationships among these biological modules
involved in prion replication delineates their temporal
coupling. We predict that for more efﬁcient inhibition of prion
replication, GAG-, cholesterol- and sphingolipid-related
processes should be targeted simultaneously. In support of
this prediction, a cocktail of a synthetic chimerical compound
(quinacrineþdesipramine) for disruption of lipid rafts
together with simvastatin for inhibition of cholesterol synth-
esis was reported to synergistically increase anti-prion activity
(Klingenstein et al, 2006).
Perturbations of pathways more prominent with one prion
strainthananotheralsomightprovidecluesonmechanismsof
targeting to speciﬁc regions of the brain or cofactors involved
intheconversionofPrP
CtoPrP
Sc.Forexample,examinationof
DEGs prominent in short incubation time strains revealed a
decreased expression for genes involved in ATP biosynthesis
in the oxidative phosphorylation pathway and increased
expression of GAG biosynthetic genes. Expression of genes
involved in cholesterol biosynthesis was signiﬁcantly
downregulated in RML prion-infected mice, but showed little
change in mice inoculated with 301V prions. Most work
toward developing anti-prion therapies has been carried out in
short incubation time systems using RML or closely related
prion isolates, suggesting that therapies for one prion strain or
onehost genotypemaynot be effective inothersituations.The
same considerations will probably hold in humans with
different phenotypic types of prion diseases emerging from
differentprion mutations andassuchindicatestheimportance
of the emerging personalized medicine—treating individuals
as individuals and not as a member of large populations (Price
et al, 2008).
Another use of the systems medicine approach is to aid in
the identiﬁcation of genes that affect the pathogenesis of prion
disease. For example, several studies have mapped genetic
modiﬁers of prion susceptibility and incubation time (Prusiner
and Kingsbury, 1985; Stephenson et al, 2000; Lloyd et al, 2001;
Manolakou et al, 2001; Moreno et al, 2003). Prion-speciﬁc
DEGs that are located in chromosomal regions containing
modiﬁergenesareprioritycandidatesfor thegenesunderlying
modulation of prion incubation time.
Genetically modiﬁed mice whose prion incubation times
reﬂect levels of PrP expression help discriminate among genes
relevant to prion replication, pathological changes, and
clinical disease. It is striking that disease progression is slow
in the heterozygous 0/þ mice, although PrP
Sc accumulates to
levels comparable to those in diseased wild-type mice long
beforeclinicalsignsoccur.Most(311/333)DEGssharedamong
B6-RML, B6-301V, B6.I-RML, B6.I-301V, and FVB-RML also
show similar patterns of change in 0/þ mice. The onset of
differential expression occurs later in 0/þ mice than in the
other combinations, presumably reﬂecting the reduced supply
ofPrP
Cforconversionto PrP
Sc,but, in mostcases,theelevated
or reduced levels of DEGs persists for a much greater
proportion of the incubation period. These results suggest
that fundamental processes are shared among 0/þ mice and
our core panel, and the long incubation time due to reduced
PrP
C levels reﬂects the time required for accumulation of
sufﬁcient neurological damage. Degradation of pathogenically
relevant PrP
Sc from the brain could also be more efﬁcient in
0/þ mice (Safar et al, 2005) and thus account for some of this
effect.
On the other hand, RML-infected Tg4053 mice, overexpres-
sing PrP, showed signiﬁcant changes in 125 of the 333 DEGs in
the shared set. Prominent shared DEGs in most of the key
shared modules exhibited similar patterns in Tg4053 mice,
though generally of smaller in magnitude and closer in time to
clinical illness and death than all other combinations (see
Figure 3). This suggests that similar pathological responses
and processes associated with prion replication are occurring
in PrP-overexpressing mice in accord with the similar end-
stage pathology typical for RML prion-infected mice. Although
perturbed networks and modules in the other combinations
were generally shared by Tg4053, there was also a unique set
of highly signiﬁcant DEGs in these transgenic mice
(Figure 2C). The very short incubation time of Tg4053 reﬂects
the increased supply of PrP
C for conversion to PrP
Sc and
expression of the Tg4053-speciﬁc DEGs changed soon after
infection. The Tg4053 set may reﬂect networks perturbed by
prion replication. Alternatively, the overexpression of PrP may
induce novel replication and disease pathways and affect cell
types that are not prominent in the other mouse strain–prion
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and the other combinations, that changes in the levels of
expression can reﬂect changes in transcription, changes in
mRNA turnover, loss of speciﬁc cell types, or loss of
specialized structures such as synapses that may harbor select
mRNAs. It is likely that our results reﬂect all of these
mechanisms. For example, the increased levels of glial DEGs
in the brain can reﬂect both activation of the cells and cell
proliferation or inﬂux of microglial precursors as suggested by
the perturbation in the leukocyte extravasation module
(Figure 5). It is also worth noting that the inconsistent and
large changes in expression that are seen in many genes after
clinical disease appears are likely to reﬂect cell death and
nonspeciﬁc changes due to illness.
Although there is clear correspondence between pathologi-
cal events and changes in gene expression in relevant
networks and modules, it is not clear which, if any, of the
changes are speciﬁc to prion infection. Not surprisingly, many
of the shared prion DEGs have been seen in other neurode-
generative diseases, where similar pathological events such as
gliosis, synaptic degeneration, and neuron loss occur.
Dynamic analysis of changes in gene expression during the
course of neurodegenerative diseases in humans is difﬁcult,
butanalyses similar toourshavebeen performedintransgenic
mouse models. Several previous studies on mice overexpres-
sing Alzheimer’s amyloid precursor protein (APP) demon-
strated involvement of similar networks. A limitation of these
studies is the failure of Tg(APP) mice to recapitulate the
neuroﬁbrillary tangles and neuron loss of Alzheimer’s
patients. Particularly informative are the kinetic analyses by
Y Wakutani and P St George-Hyslop (personal communica-
tion) on the perturbation of inﬂammatory pathways as
amyloid accumulates in Tg(APP)CRND8 mice; these changes
are similar to those seen in prion infection. Although no
appreciable neuron loss occurs in TgCRND8 mice, synaptic
loss and behavioral changes are observed. Overall, of 86 DEGs
observed in TgCRND8 mice, 37 were observed as shared
in our study (see Supplementary Tables S1 and S2) were
seen as RML prion strain-enriched DEGs. Notable differences
in DEG sets between prion-infected mice and TgCRND8
include the absence of PRR-related genes in TgCRND8 mice,
whereas complement genes and glial markers are shared
between the two disease models. Although similar processes,
such as lipid metabolism, were perturbed in both systems,
individual DEGs or the direction of changes for the same DEGs
oftendiffered.Most interesting examplesaregenesinvolved in
cholesterol biosynthesis: these genes were decreased in RML
prion-infected mice, whereas they were upregulated in
TgCRND8 mice. Whether any of the DEGs that appear to be
markers for prion infection actually are speciﬁc for prion
disease will require further investigation. It is striking that
even including our novel modules, nearly one-third of our
shared DEGs could not be assigned to a hypothetical prion
disease network. Such genes represent the ‘dark genes’ of
prion disease and suggest that all diseases will be far more
complex than initially thought. This is a compelling argument
for using the global or comprehensive analyses of systems
approaches.
Although associating DEGs to pathological events is
relatively straightforward, identifying genes as speciﬁcally
involved in or perturbed by the process of conversion of PrP
C
toPrP
Scis moredifﬁcult.Additionofbrainhomogenate greatly
facilitates the conversion of puriﬁed PrP
C in vitro protein-
mediated cyclic ampliﬁcation reactions (Soto et al, 2005) and
an unknown factor that binds to a C-terminal region of PrP
may be limiting for cross-species transmission as a facilitator
of conversion (Kaneko et al, 1997). Various prion infection-
speciﬁc DEGs have been reported in N2a cells, which do not
exhibit severe cellular abnormalities due to prion replication.
However, systematic analysis of N2a sublines independently
infected with scrapie prions did not reveal any set of shared
DEGs indicative of prion infection that were common to all
sublines (Chasseigneaux et al, 2008). Although this is likely
due to the instability and aneuploidy of N2a cells, the
possibility that gene expression is only moderately perturbed
by the conversion process must be considered. The fact that
mRNA levels for arguably the most important molecule in
priondisease,PrP,donotchangeduringthecourseofinfection
was conﬁrmed in this study (difference of the Prnp mRNA
levels between infected and normal brains were not signiﬁ-
cant). This lack of change originally led some to conclude that
PrP was not central to disease (Chesebro et al, 1985). Other
post-translational changes, such as elevation of the Notch
intracellular domain that has been demonstrated to play a role
inpriondisease(Ishikuraetal,2005),wouldnotbedetectedin
our study. Similarly, levels of the PrP-related protein Shadoo
have been reported to decrease in prion-diseased mice (Watts
et al, 2007), but expression of its mRNA (Sprn) is unchanged;
the relevance of changes in Shadoo levels to prion disease is as
yet uncertain.
A systems approach to discover early, reliable diagnostic
markers has drawn signiﬁcant attention in prion disease
because deﬁnitive diagnosis currently requires post-mortem
immunological analysis of brain tissues (Safar et al, 1998;
Soto, 2004; Glatzel et al, 2005). As an alternative, early and
reliable blood assays would be very desirable, especially to
prevent the spread of the disease through blood transfusion or
consumption of prion-infected animal meat. Currently,
advanced blood assay technologies still focus on the detection
of very low levels of PrP
Sc in blood. Cyclic ampliﬁcation of the
PrP
Scproteinfrombloodofaffectedanimalshasbeenachieved
(Saa et al, 2006), but sensitivity is as yet too low (only 60% of
prion-infected animals tested positive) for routine application
to preclinical diagnosis. In this regard, the shared DEGs
uniquely associated with prion pathophysiology and secreted
into the blood offer new opportunities for the identiﬁcation of
diagnostic marker candidates for robust blood assays, as some
of the expression changes are expected to be reﬂected as
changes in the levels of disease-perturbed brain proteins
secreted into the peripheral blood. Preliminary observations
suggest that thiswillbea powerful approachto earlydiagnosis
of prion disease. H Yoo and L Hood (unpublished observa-
tions) used selected prion-speciﬁc DEGs as biomarker
candidates in conjunction with mass spectrometry-based
proteomics analyses to identify multiple secreted proteins as
potential diagnostic serum biomarkers of prion disease. The
important point is that a systems approach to disease will,
through the formulation of testable hypotheses, lead to deeper
mechanistic insights into the disease process and will as well
lead to powerful new approaches to early (preclinical)
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perturbed networks to make them behave in a more normal
manner—or at least abrogate the more deleterious aspects of
their function). In a more conventional approach to therapy,
this network analysis will reveal key nodal points that may
themselves become targets for drugs. In either case, the
systems approach to disease does open up powerful new
approaches to the identiﬁcation of targets for drug therapy.
It is clear that these network studies reﬂect the dynamics of
the prion infectious process—at this time they have not
provided insights into the initiating mechanism(s) of disease.
We should stress that there are not a sufﬁcient number of
informative time points during the early stages of the prion
disease to identify the initial changes induced by infection.
Moreover, the dilution of signal from these earliest changes
that would have occurred initially in a small number of cells
mightwellbebeyondtheresolutionofthesestudiesconducted
on whole brain, suggesting that early samples of thalamus,
where prion replication is ﬁrst detected, may be more
informative. In spite of this, we have detected dynamically
changing series of brain networks that have relevance to the
changing pathophysiologyof the disease. We plan to followup
these studies with the infection of CNS stem cell-containing
brainneurospheresinvitro(Girietal,2006).Inthesecelllines,
we should be able to detect veryearly events, at the expense of
losing the context of the intact brain and its multiplicity of
cellular interactions.
We have demonstrated here the power of comprehensive,
global approaches to systems as complex as prion disease,
even when the data sets are restricted to gene expression
proﬁles,and involvewhole brain.The efﬁcacyof using several
strain combinations, prion and genetic backgrounds as a
biological ﬁlter to deal with signal-to-noise issues and identify
the network signals that are important for various disease-
related processes is a striking lesson from our study. The new
modules that have been connected to the disease, the strong
alignment of the speciﬁc pathogenic processes with network
changes, and the range of novel and sharpened hypotheses
illustrate the power of this approach. We have conﬁdence that
with the addition of other data types, the attribution of
network processes to brain regions and cell types, and the
speciﬁc testing of hypotheses suggested here, that the systems
medicine of prion disease (and other neurodegenerative
diseases) will advance rapidly.
Materials and methods
Mice and scrapie infection
B6, B6.I, FVB, 0/þ, 0/0, and Tg4053 mice were used. Female mice
(C57BL/6andothers)wereinoculatedintracerebrallyat5weeksofage
with 10ml of 10% brain homogenate from clinically ill mice or normal
control mice. Two prion strains were used: RML and 301V. Mice were
killed at the intervals indicated in Table I for RNA preparation and
brain histoblots. Clinical signs at the time of killing were noted.
RNA preparation and microarray analysis
Total RNAwas extracted fromeach mouse brain using TRIZOL reagent
(Invitrogen, USA), was treated with DNase I (Ambion), and further
puriﬁed with RNeasy columns (Qiagen, USA). Qualityof RNA samples
was evaluated by using BioAnalyzer (Agilent, USA). Here, 5mgo f
total RNA was reverse transcribed and followed by generation of
double-stranded cDNAs. The resulting double-stranded cDNAs were
puriﬁed and biotinylated to cRNAs. The labeled antisense cRNAs were
fragmented and hybridized to GeneChip Mouse Genome 430 2.0 Array
(Affymetrix, USA), which contains 45000 probe sets. The hybridiza-
tion was carried out for 16h at 451C. The arrays were washed and
stained with streptavidin phycoerythrin using a GeneChip Fluidics
Station 450 (Affymetrix) and scanned using a GeneChip scanner 3000
(Affymetrix). The scanned images of the arrays were converted and
imported into the ISB’s Systems Biology Experiment Analysis System
(SBEAMS) for array data normalization and further analyses.
Identiﬁcation of shared DEGs across the ﬁve
prion–mouse combinations
To identify the genes involved in essential processes related to prion
pathogenesis, we identiﬁed the DEGs with shared differential
expression patterns in ﬁve prion–mouse combinations (B6-RML,
B6.I-301V, B6-301V, B6.I-RML, and FVB-RML). The following method
was applied: (i) log2 median ratios at each time point were computed
in all ﬁve core combinations; (ii) the time points in each prion–mouse
combination are normalized by its incubation time, and the log2
median ratios for each gene at the normalized time points are then
scaled into those with zero mean and unit variance; (iii) these scaled
median ratios from the ﬁve combinations were combined, and a
smoothing line was then ﬁt using super smoothing method (Friedman
and Stuetzle, 1982) to the combined median ratios to compute a
goodness of ﬁt measure, a normalized ratio of sum of squared
regression to sum of squared error (Supplementary information)—for
a gene whose normalized temporal expression patterns are well-
correlated, a high goodness of ﬁt measure is produced; (iv) to perform
an empirical statistical hypothesis testing, a control data set was
generated using Monte Carlo simulation by randomly sampling the
ﬁve combination data (Supplementary information); (v) goodness of
ﬁt measures were then computed for the genes in the randomly
sampleddataset—thecomputedgoodnessofﬁtmeasuresarenotlarge
because they should not be systematically correlated in the random
data;(vi)anullhypothesisdistribution(pdf(H0))wasthenempirically
driven using Gaussian kernel density estimation for the computed
goodness of ﬁt measures; and (vii) a P-value of a gene being correlated
by chance across the ﬁve combinations was then calculated using
pdf(H0)byone-sidedtestofthecorrespondinggoodnessofﬁtmeasure
computed in step (iii) (Supplementary information). A gene with a
small P-value shows well-shared patterns across the ﬁve core
combinations. In addition to the correlation in temporal expressions,
the shared DEGs should also be differentially expressed in all
combinations (Supplementary information). Thus, P-values of genes
being differentially expressed in all ﬁve combinations were computed
by combining the ﬁve P-values (Supplementary information). Finally,
both P-values for correlation and combined P-values for differential
expression are then combined using Stouffer’s method (Hwang et al,
2005), resulting in the overall P-values of genes showing shared
differential temporal patterns. A gene with a small overall P-value
shows well-shared differential patterns. To stringently identify the
shared DEGs, we selected shared DEGs using a cutoff for the overall
P-values of 10
 3. Then, we further removed potential false positives as
follows: for each selected shared DEG, (1) the maximum P-value
(Pmax) ofthose computedfordifferentialexpression inthe ﬁvemouse–
prion combinations (PB6-RML, PB6.I-301V, PB6-301V, PB6.I-RML, and
PFVB-RML; Supplementary information) was computed; (2) the
maximum absolute fold changes in the individual combinations
(Tmax(B6-RML), Tmax(B6.I-301V), Tmax(B6-301V), Tmax(B6.I-RML),
and Tmax(FVB-RML)) were computed; and (3) the selected genes were
consideredandremovedasfalsepositivesifatleastoneoftheﬁvePmax
values was larger than 0.1 and at least one of the ﬁve Tmax values from
the ﬁve combinations was smaller than 1.5 at the same time.
Typicaltimecourse analysesmainlydetectdifferentialexpressionin
the individual time course data (Supplementary information). Unlike
these methods, our method focuses on detecting shared patterns
among differential expression from multiple time course data sets
differinginnumbersoftimepoints,samplingintervals,andtimespans
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multiple time course data sets.
Identiﬁcation of incubation time- and
prion-speciﬁc genes
Toidentifythegenesinvolvedinbiologicalprocessesthatareactivated
only in mice with short incubation times and also a particular prion
strain, the following method was applied: (i) a training set of the genes
showing incubation time-speciﬁc (or RML-speciﬁc) differential
expression was identiﬁed by examining false positives that were
removed from the shared DEGs selected with a relaxed cutoff of
Po0.01; (ii) after smoothing expression proﬁles of the genes in the
training set using a moving average method (window size¼5), the
reference temporal proﬁles were deﬁned for the genes in the training
set as the median proﬁle of smoothed log2 temporal ratios; (iii) for
each gene, the correlation (also t-statistic value) of the smoothed log2
temporal proﬁle with the reference proﬁle was computed; (iv) as
done in the previous empirical statistical hypothesis testing, the
null hypothesis distribution was then estimated after generating
a randomized control data set and computing the correlation and
t-statistic values with the reference proﬁle; and (v) using pdf(H0), a
P-value was computed for each gene. Finally, a set of incubation time-
speciﬁc (or RML-speciﬁc) genes was identiﬁed using a stringent cutoff
(Po10
 4). We also further removed potential false positives when a
P-value for differential expressions in short incubation time (or RML)
combinations was at least larger than 0.1 and also a P-value in long
incubation time (or FVB) combinations was at least less than 0.1,
respectively. See further details in the Supplementary information.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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